Literature DB >> 8892897

Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines.

U Junker1, S Escaich, I Plavec, J Baker, F McPhee, J R Rose, C S Craik, E Böhnlein.   

Abstract

The enzymatic activity of the human immunodeficiency type 1 (HIV-1) protease (PR) is crucial to render HIV-1 virions mature and infectious. Hence, genetic intervention strategies based on trans-dominant (td) variants of the HIV-1 PR might be an alternative to current pharmacological and gene therapy regimens for AIDS. CD4-positive human CEM-SS T-cell lines were generated which constitutively expressed HIV-1 td PR variants. HIV-1 infection experiments demonstrated severely reduced HIV-1 replication in these td PR CEM-SS cell lines compared with control T cells expressing wild-type PR. Furthermore, replication of an HIV-1 isolate bearing a PR inhibitor-resistant PR was blocked, showing that genetic intervention strategies based on td PRs can be effective against HIV-1 isolates containing PR inhibitor-resistant mutants.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892897      PMCID: PMC190846     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Regulation of HIV-1 gene expression.

Authors:  B R Cullen
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

2.  Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.

Authors:  D J Kempf; K C Marsh; D A Paul; M F Knigge; D W Norbeck; W E Kohlbrenner; L Codacovi; S Vasavanonda; P Bryant; X C Wang
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Form, function, and use of retroviral gag proteins.

Authors:  J W Wills; R C Craven
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

4.  Inhibition of HIV protease activity by heterodimer formation.

Authors:  L M Babé; S Pichuantes; C S Craik
Journal:  Biochemistry       Date:  1991-01-08       Impact factor: 3.162

5.  A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.

Authors:  T J McQuade; A G Tomasselli; L Liu; V Karacostas; B Moss; T K Sawyer; R L Heinrikson; W G Tarpley
Journal:  Science       Date:  1990-01-26       Impact factor: 47.728

6.  HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus.

Authors:  D Trono; M B Feinberg; D Baltimore
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

7.  Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.

Authors:  K A Page; N R Landau; D R Littman
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator.

Authors:  D Bevec; M Dobrovnik; J Hauber; E Böhnlein
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

9.  Detection of intracellular HIV-1 Rev protein by flow cytometry.

Authors:  R J Rigg; J S Dando; S Escaich; I Plavec; E Böhnlein
Journal:  J Immunol Methods       Date:  1995-12-27       Impact factor: 2.303

10.  Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.

Authors:  M H Malim; W W Freimuth; J Liu; T J Boyle; H K Lyerly; B R Cullen; G J Nabel
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more
  5 in total

1.  HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activity.

Authors:  Kwang Soon Kim; Dong Bin Jin; So Shin Ahn; Ki Seok Park; Sang Hwan Seo; You Suk Suh; Young Chul Sung
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

2.  Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.

Authors:  M Shehu-Xhilaga; S M Crowe; J Mak
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  The protease and the assembly protein of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8).

Authors:  A Unal; T R Pray; M Lagunoff; M W Pennington; D Ganem; C S Craik
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

4.  Novel macromolecular inhibitors of human immunodeficiency virus-1 protease.

Authors:  Gabriella Miklóssy; József Tözsér; János Kádas; Rieko Ishima; John M Louis; Péter Bagossi
Journal:  Protein Eng Des Sel       Date:  2008-05-13       Impact factor: 1.650

5.  Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

Authors:  Johanna Wapling; Seema Srivastava; Miranda Shehu-Xhilaga; Gilda Tachedjian
Journal:  Drug Target Insights       Date:  2007-07-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.